Bank & Trust Co Buys New Stake in Moderna, Inc. (NASDAQ:MRNA)

Bank & Trust Co bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 306 shares of the company’s stock, valued at approximately $36,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MRNA. Ogorek Anthony Joseph NY ADV acquired a new position in Moderna in the fourth quarter valued at approximately $27,000. Arlington Trust Co LLC grew its holdings in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after buying an additional 290 shares in the last quarter. Cedar Wealth Management LLC increased its stake in Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the last quarter. Westside Investment Management Inc. purchased a new position in Moderna during the first quarter worth about $32,000. Finally, Rise Advisors LLC raised its position in Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after purchasing an additional 286 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, President Stephen Hoge sold 255 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the sale, the president now owns 1,486,508 shares of the company’s stock, valued at approximately $179,808,007.68. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, President Stephen Hoge sold 255 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the sale, the president now owns 1,486,508 shares in the company, valued at $179,808,007.68. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Shannon Thyme Klinger sold 1,296 shares of Moderna stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total transaction of $210,561.12. Following the sale, the insider now owns 10,623 shares in the company, valued at approximately $1,725,918.81. The disclosure for this sale can be found here. In the last ninety days, insiders sold 396,239 shares of company stock worth $55,563,937. 15.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

MRNA has been the subject of several recent research reports. UBS Group raised their price objective on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. William Blair restated a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Royal Bank of Canada downgraded Moderna from an “outperform” rating to a “sector perform” rating and decreased their price objective for the company from $125.00 to $90.00 in a report on Monday. Barclays cut their target price on shares of Moderna from $168.00 to $155.00 and set an “overweight” rating on the stock in a report on Friday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $122.79.

Moderna Stock Performance

Shares of MRNA stock traded down $1.45 during trading hours on Tuesday, reaching $82.30. The stock had a trading volume of 5,116,690 shares, compared to its average volume of 4,162,379. The firm has a 50-day simple moving average of $126.74 and a 200-day simple moving average of $114.99. The firm has a market capitalization of $31.54 billion, a PE ratio of -5.25 and a beta of 1.67. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.91. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period in the previous year, the company earned ($3.62) earnings per share. Moderna’s revenue was down 29.9% compared to the same quarter last year. As a group, equities analysts forecast that Moderna, Inc. will post -7.46 earnings per share for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.